Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We ar... more >

Stock Quotemore >
$2.73
0.00 (0.00%)
Bellerophon (Nasdaq: BLPH)
Data as of 07/18/18 3:20 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
06/12/18
Bellerophon Therapeutics to Participate on Panel at JMP Securities Life Sciences Conference
WARREN, N.J., June 12, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will participate on a panel, titled Emerging Landscape of Treatment Options in PAH, at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018, in New York City. The conference is taking place June 20-21, 2018, at The St. Regis New York. Bellerophon Presentation Details Title:        ... 
05/16/18
Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference
WARREN, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will present the previously reported top-line results from its Phase 2 study evaluating the use of INOpulse® in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) at the American Thoracic Society (ATS) 114th International Conference, on Monday, May 21, 201... 
05/10/18
Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results
WARREN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended March 31, 2018. “We continue to achieve significant progress in our clinical trials and expect multiple important and  potentially value enhancing catalysts for our INOpulse® programs throughout the course of 2018,” said Fabian Tenenba... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources